Ignite Creation Date:
2025-12-25 @ 3:33 AM
Ignite Modification Date:
2026-02-17 @ 7:22 PM
Study NCT ID:
NCT04014205
Status:
UNKNOWN
Last Update Posted:
2023-04-18
First Post:
2019-06-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ICP-CL-00107
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None